BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 12809960)

  • 1. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
    Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
    Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
    Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
    Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C; Kalogeropoulos S; Latsios GS; Hartzoulakis G; Kalogeropoulos G; Zaharof A
    Int J Clin Pharmacol Res; 2002; 22(3-4):85-8. PubMed ID: 12837045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
    Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
    Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.